Top in GI: Long-term Entyvio use, ACG guidance on achalasia

Long-term data from the GEMINI trial showed that Entyvio maintained its favorable safety profile in patients with inflammatory bowel disease over 8 years. It was the top story in gastroenterology last week.

Another top story was about new guidelines from the American College of Gastroenterology (ACG) for diagnosing and treating patients with achalasia.

Read these and more top stories in gastroenterology below:

GEMINI: Entyvio safety profile favorable in long-term use

The safety profile of Entyvio (vedolizumab, Takeda) remained favorable through 8 years of use in patients with inflammatory bowel disease (IBD), according to recent data. Read more.

ACG develops clinical guidelines for diagnosis, treatment of achalasia

ACG recently released clinical guidelines to diagnose and treat patients with achalasia, a rare disorder that affects only 20,000 to 40,000 patients in the United States, according to researchers. Read more.

Remicade plus thiopurine for Crohn’s yields better outcomes in first 6 months

Remicade (infliximab, Janssen) plus optimized thiopurine was superior in patients with Crohn’s disease compared with infliximab monotherapy for response initiation, durability and clinical outcomes in the first 6 months after induction, according to recently published study results. Read more.

Comorbidities, not age, linked with worse safety outcomes for Entyvio, Stelara

Patients who received vedolizumab or Stelara (ustekinumab, Janssen) for IBD who had more comorbidities were at an increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics. Read more.

Seven recent reports in interventional endoscopy

Healio presents recent reports in endoscopy, including new developments on balloon-assisted enteroscopy, the current state of endoscopic education and how doctors across the country reopened their endoscopy centers in the wake of the COVID-19 pandemic. Read more.